In addition, it has been shown in ovarian cancer and sarcoma cells expressing constitutively active JAK2 that cisplatin significantly inhibited tyrosine phosphorylation and kinase activity of JAK2 in a dose- and time-dependent manner [29]. The gene discussed is JAK2; the disease is ovarian cancer.